Welcome to our dedicated page for Avidity Biosciences SEC filings (Ticker: RNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking Avidity Biosciences’ journey from lab bench to potential FDA approval means wading through dense disclosures on its Antibody Oligonucleotide Conjugate platform, clinical trial costs, and collaboration milestones. Those details hide in 200-page 10-Ks and rapid-fire 8-Ks—documents few investors have time to dissect.
Stock Titan eliminates that bottleneck. Our AI turns every Avidity Biosciences quarterly earnings report 10-Q filing, annual report 10-K simplified, and Avidity Biosciences 8-K material events explained into plain-English highlights within minutes of hitting EDGAR. Need to monitor Avidity Biosciences insider trading Form 4 transactions? We stream Form 4 insider transactions real-time, flag executive stock sales, and cross-reference them with upcoming data releases.
- AI-powered summaries clarify R&D spend, cash runway, and AOC pipeline milestones.
- Real-time alerts for Avidity Biosciences executive stock transactions Form 4.
- Side-by-side trend charts for revenue from collaborations and quarterly burn.
- Keyword search—find “del-desiran Phase 2 costs” inside hundreds of pages instantly.
Whether you’re comparing dilution risk before the next capital raise or studying compensation in the Avidity Biosciences proxy statement executive compensation, our platform answers the questions investors actually ask: “How healthy is the balance sheet?”, “Which trials are fully funded?”, “What did the CEO buy last quarter?”. Stop scrolling; start understanding Avidity Biosciences SEC documents with AI.
Form 144 summary for Avidity Biosciences (RNA): The filing notifies a proposed sale of 30,914 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,182,769.64, scheduled for 08/06/2025. The securities were acquired as Performance Stock Units from the issuer on 12/17/2024 (amount 30,914; date of payment listed as 12/17/2024; nature of payment: N/A). The filing reports "Nothing to Report" for securities sold in the past three months. Several filer identification and notice fields (CIK, submission contact name, date of notice) are blank or not provided in the document, limiting disclosure.
FAQ
What is the current stock price of Avidity Biosciences (RNA)?
What is the market cap of Avidity Biosciences (RNA)?
